We recently released a list 11 Now Unstoppable Growth Stocks Now Invest. In this article, we will look at Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) position with other unstoppable growth stocks.
BlackRock stressed that the trade conflict between the United States and China continues to cause significant economic damage. However, U.S. expectations for supply-driven contractions are very different from typical business cycle recessions. Tough economic rules that bind policy are expected to limit damage. Furthermore, despite expecting volatility, AI large forces have been making the company's increase in U.S. stocks and positive for advanced market stocks.
BlackRock believes that some sectors are more vulnerable to tariffs than others, and sectoral differences have played a role in the 2025 revenue issuance in Q1. AI Mega Force's cutting-edge companies continue to maintain the strength of U.S. stocks, while policy uncertainty and uncertainty affect the market more. Leading technology companies managed to exceed earnings expectations in the first quarter, highlighting the growing demand driven by AI and announcing plans to increase investments focused on AI.
This trend reinforces the fact that despite supply-driven disruption, how large AI forces continue to continue. As a result, BlackRock maintained a positive attitude towards developed market (DM) stocks (mainly the United States). On the other hand, the company has marked automakers as the ones most vulnerable to key supply inputs in China. In addition, some automakers have highlighted the tariff expectations for full-year earnings.
Also read: 7 Best Stocks to Buy Long-Term and 8 Cheap Jim Cramer Stock Investing.
Franklin Templeton believes it is crucial to remember that tough economic and/or market stages are limited. Investors who tend to see most profits during recovery are those who stayed in stormy weather. The investment company continues to see an increase in potential during the ongoing small-cap leadership period. Franklin Templeton said that given its selection metrics that measure index valuation, EV/EBIT, the Russell 2000 is more attractive than the Russell 1000.
According to investment managers, valuations become more attractive when including consensus earnings growth. It is worth noting that growing stocks can increase their earnings faster than ordinary businesses in various industries or in broader markets. By the end of 2024, the 2025 Russell 2000 is expected to receive higher revenue growth in 2025 compared to the EPS-based Russell 1000.
To list the 11 unstoppable growth stocks currently invested, we use filters to cater to the growth sector with 3-year revenue growth of at least about 25% and are highly appreciated on the YTD basis. We also mentioned hedge fund sentiment around each stock as of the fourth quarter of 2024. Finally, stocks are arranged in the rising order of their hedge fund sentiment.
Note: The data was recorded on May 9th.
Why are we interested in stocks that hedge funds to accumulate? The reason is simple: Our research shows that we can beat the market by mimicking the top stocks of the best hedge funds. Our strategy for quarterly newsletters selects 14 small and large stocks every quarter, returning 373.4% since May 2014, beating its benchmark by 218 percentage points (See more details here).
Biotechnologists wear lab coats to create unique formulas for treatment.
Number of hedge fund holders: 21
3-year revenue growth: ~51.9%
Increase of YTD: ~44.8%
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a biopharmaceutical company dedicated to the development and commercialization of therapies in Illinois. Oppenheimer raised the company's price target to $7 from $6 and rated its stock as "outperforming the market." The company noted Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) reported a total revenue of $60.1 million for Q1 2025, the highest revenue estimated by the company/consensus. For Reporlev®, net income for the first quarter was $25.5 million, reflecting a year-on-year increase of about 141%. This increase is supported by the fact that the average number of patients in Recorlev® increased by 124%. For GVOKE®, the price of Q1 net income in 2025 was USD 20.8 million, up about 26% year-on-year. Oppenheimer also believes that since the manufacturing industry is entirely domestic, there is no obvious tariff threat from the company.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) performance shows sustained momentum throughout the portfolio, a healthy need for Recorlev®. Recorlev® has always distinguished itself as the fastest growing company and is now its largest product, a unique differentiation therapy for patients with high cortical solutes and endogenous Cushing syndrome. It has exacerbated its fiscal 2025 total revenue guidance to $260 million-$275 million due to its strong Q1 2025 performance and healthy momentum in the business. The revision comes from the previous $255 million-$275 million.
Overall, Xers Ranked 11th In our list of unstoppable growth stocks investing now. While we acknowledge the potential of XER is an investment, our belief is that some undervalued AI stocks have greater hope of offering higher returns and do so in a shorter time frame. AI stocks have risen since the beginning of 2025, while popular AI stocks have lost about 25%. If you are looking for an undervalued AI stock that is more promising than XERS but has less than 5 times its revenue, check out our report Cheapest AI stocks.
Read the next article: Buy 20 Best AI Stocks Now and According to the billionaire, there are now 30 best stocks.
Disclosure: None. This article was originally published in Internal monkey.